23 November 2020 in The Oncologist
Background The combination of everolimus (EVE) and exemestane (EXE) is approved for the treatment of metastatic hormone receptor‐positive breast cancer (mHRBC) patients who progress on non‐steroidal aromatase inhibitor (NSAI) therapy. However, none of the subjects enrolled in the trial that led to this approval (BOLERO‐2) had previously received CDK4/6 inhibitors (CDK4/6is), which have since become a frontline standard of care for mHRBC. As such, the clinical benefit of EVE + EXE in patients who have previously received CDK4/6is remains unknown. Methods Adult mHRBC patients at our institution who progressed on a NSAI + CDK4/6i or NSAI therapy alone and were treated with at least one cycle of EVE + EXE between 2012 and 2018 were analyzed. Collected data included patient demographics, treatment history, adverse events, and clinical outcomes. Primary objectives were to compare progression‐free survival (PFS) and overall survival (OS) between patients who received prior NSAI + CDK4/6i therapy versus a NSAI alone. Results Among 43 patients, 17 had prior CDK4/6i exposure. With the exception of de novo metastatic disease, patient and disease characteristics were comparable across treatment cohorts. There was no significant difference in PFS (median 3.6 vs 4.2 months) or OS (median 15.6 vs 11.3 months) between patients who had received prior CDK4/6is and those who had not, respectively. Conclusion Prior exposure to CDK4/6i therapy did not impact survival outcomes for mHRBC patients taking EVE + EXE. However, there was a trend towards improved OS in the CDK4/6i cohort that should be evaluated in larger cohorts. Implications for Practice The use of CDK4/6 inhibitors in combination with a non‐steroidal aromatase inhibitor has become a standard frontline therapy in metastatic hormone receptor‐positive breast cancer. An approved subsequent line of therapy is everolimus plus exemestane however the original data supporting this therapy predated prior of approval CDK4/6 inhibitors. As such, the clinical benefit of everolimus and exemestane in patients previously treated with a CDK4/6i was unknown. This retrospective cohort study offers real world data demonstrating prior CDK4/6 inhibitor exposure does not impact survival outcomes for everolimus plus exemestane.
1 December 2023 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Asthma susceptibility is influenced by environmental, genetic, and epigenetic factors. This study shows that maternal allergen exposure during pregnancy promotes unique epigenetic trajectories in second-generation offspring at baseline and in response to allergen sensitization, which is associated with the potentiation of airway hyperreactivity. These effects are one mechanism by which maternal asthma may influence the inheritance of asthma risk.
1 April 2021 in JCO Oncology Practice
BACKGROUND: Determination of the comparative efficacy of one therapy over another for hepatocellular carcinoma (HCC) can be challenging. Application of a recognized value framework to published studies could objectively compare the potential benefit across available therapies. MATERIALS AND METHODS: An umbrella review of phase III trials for HCC therapies was performed. ASCO Value Framework Net Health Benefit Score version 2 (ASCO-NHB v2) scores, the primary analysis, and European Society of Medical Oncology Magnitude of Clinical Benefit Scale version 1.1 scores, the secondary analysis, were computed using selected drug registration trials. Both scores were compared between drugs that were Food and Drug Administration (FDA)-approved by 2020 and those that were not. RESULTS: Of the 22 studies identified, nine were FDA-approved and 13 were not. Across 22 trials, the median overall survival (OS) was 9.2 months (range, 1.9-16.4 months), with a median gain of 0.35 month (range, 2.3-3.3 months). HCC therapies that were FDA-approved showed longer OS (median 10.7 v 7.9 months, P < .01) and higher ASCO NHB scores (+18.4 v −5.7 scores, P < .01). The median gain in OS was 2.2 months in the approved treatments compared with −0.3 months in the unapproved group, with no difference in progression-free survival between the two groups. CONCLUSION: The nine FDA-approved therapies for HCC have higher mean NHB score than those that were not FDA-approved. The application of ASCO-NHB v2 and other proposed value frameworks could examine data of future therapies for HCC through a patient-oriented approach.